Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081588 · ClinicalTrials.gov registry record · Phase 2
An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.
A Phase 2 study, sponsored by Tibotec Pharmaceuticals, Ireland.
- Completed
- Registry status
- Phase 2
- Development phase
- 555
- Enrollment target
NCT00081588 is a Phase 2 study that has completed, run by Tibotec Pharmaceuticals, Ireland. The registered enrollment target is 555 participants.
The verdict
NCT00081588, a Phase 2 study, has completed, sponsored by Tibotec Pharmaceuticals, Ireland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 555 participants
- Enrollment target
Study Summary
The primary objective of the TMC114-C215 study is to evaluate the safety and tolerability of TMC114/RTV over time. The secondary objectives are to evaluate the antiviral activity over time and to evaluate the immunological effect over time.
Interventions
- DRUG TMC114
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 555 participants |
| Start Date | 2003-11 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00081588
The ClinicalTrials.gov registry entry for NCT00081588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 555 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tibotec Pharmaceuticals, Ireland, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TMC114 is the first listed.
NCT00081588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00081588 about?
NCT00081588 is a clinical study titled "An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.". The primary objective of the TMC114-C215 study is to evaluate the safety and tolerability of TMC114/RTV over time. The secondary objectives are to evaluate the antiviral activity over time and to evaluate the immunological effect over time.
What is the current status of trial NCT00081588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 555 participants. The study started on 2003-11. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00081588?
The interventions under investigation include: TMC114 (DRUG).
Who is sponsoring clinical trial NCT00081588?
This trial is sponsored by Tibotec Pharmaceuticals, Ireland, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.